John C. Hayes is editor of Diagnostic Imaging.
Sometimes we get to explore a controversy with a bit of historical perspective. That opportunity usually involves someone who has spent considerable time in radiology and has developed strong opinions about what the history shows. We have just such an example in a commentary from Prof. Dr. Peter Rinck that appears on page 23 of this edition.
Rinck, an expert in MR contrast, looks at the association of nephrogenic systemic fibrois and gadolinium. Probably better than anyone else, Rinck has the clinical and scientific knowledge, along with the business perspective, that allows him to reach some interesting conclusions about how this problem came about.
Some of what he reports those of us who have followed the NSF controversy know already: for example, that cyclic agents are less likely to be associated with NSF than linear agents. But there is much here that is new and reflects Rinck's considerable experience in the field, including inside knowledge gained as an instructor who taught physicians and vendor representatives about the mechanisms of gadolinium contrast.
As is appropriate in this setting, Rinck also imparts lessons learned. Coming in for criticism is an industry that failed to heed some of the warning signs and, especially, radiologists who pursued off-label gadolinium uses without fully understanding the mechanisms at work.
Rinck's column is a provocative article and worth your attention.
John C. Hayes is editor of Diagnostic Imaging.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.